Deciphera Pharmaceuticals Inc. (DCPH)
Symbol Info
Listed Symbol DCPH
Name Deciphera Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-2.83
Price Info
21 Day Moving Average $33.8900
21 Day EMA $33.915820
50 Day Moving Average $34.8954
50 Day EMA $32.927180
200 Day EMA $28.635800
200 Day Moving Average 26.946950
52 Week High $42.99
52 Week Low $18.55
52 Week Change $25.706900
Alpha 0.033629
Beta 1.8717
Standard Deviation 0.228242
R2 0.113276
Periods 25
Share Information
10 Day Average Volume 252,261
20 Day Average Volume 357,437
30 Day Average Volume 445,898
50 Day Average Volume 916,999
Outstanding Shares 50,647,539
Float Shares 50,554,039
Percent Float 99.82%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 216
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 2,956,423
Institute Holdings Percent 76.500000
Institute Sold Previous 3 Months 1,314,897
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 93,500
Price Change
7 Day Price Change $1.6899986
7 Day Percent Change 5.19%
21 Day Price Change $1.6800003
21 Day Percent Change 5.16%
30 Day Price Change $-1.6800003
30 Day Percent Change -4.68%
Month To Date Price Change $0.2900
Month To Date Percent 0.85%
90 Day Price Change $13.580000
90 Day Percent Change 65.76%
Quarter To Date $0.290001
Quarter To Date Percent 0.85%
180 Day Price Change $10.779999
180 Day Percent Change 45.97%
200 Day Price Change $10.480000
200 Day Percent Change 44.13%
Year To Date $13.240000
Year To Date Percent 63.08%
Profile
Description Deciphera Pharmaceuticals Inc is a biotechnology company, develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib.
Details
Issue Type CS
Market Cap $1,733,665,260
Sec Type
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 50,647,539
CEO Steven L. Hoerter
Employees 114
Last Audit UE
Classification
CIK 0001654151
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 500 Totten Pond Road
6th Floor
Waltham, MA 2451
Website https://www.deciphera.com
Facisimile +1 785 830-2150
Telephone +1 781 209-6400
Email cmorl@deciphera.com
Key Ratios
Profitability
EBIT Margin -502
EBITDA Margin -500.4
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $25,000,000
Revenue Per Share $0.4936
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $1,455,734,393
Price To Sales 69.346610
Price To Free Cash -17.2
PE High Last 5 Years -
Price To Book 7.5
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 7.5
Financial Strength
Total Debt To Equity 0.0
Int Coverage -1,588.6
Current Ratio 7.3
Leverage Ratio 1.2
Quick Ratio 7.1
Long Term Debt To Capital 0.01
Assets
Receivables Turnover 2.0
Invoice Turnover -
Assets Turnover 0.10
Management Effectiveness
Return Assets -40.58
Return On Equity -46.03
Return On Capital -45.9
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
DCPH
Deciphera ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.